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Abstract 
The status of liver transplantation is reviewed with emphasis 
upon the current survival statistics and the quality of life to 
be expected in survivors. Present day indications and contra-
indications for the procedure are reviewed. The operative procedure 
and the peri-operative problems which are to be expected following 
a successful transplant are discussed. 
The first orthotopic liver transplant performed in a human 
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was accomplished in March 1963 . Since thai time, over 500 such 
procedures have been performed worldwide The vast majority, 
however, have been performed by a single surgical team headed 
by Thomas E. Starzl at the University of Colorado and since 1981 
at the University of Pittsburgh. Moreover,since relocating at the 
University of Pittsburgh, the performance rate of the procedure 
has accelerated such that Dr. Starzl's entire experience prior 
to 1981 (extending over an 18-year period) has been duplicated in 
2 less than 3 years . More important than the frequency of performance, 
both to the patient and referring physician however,is the recent 
dramatic improvement in survival figures achieved with liver trans-
3 plantation Prior to 1980, the best survival figures ranged 
from 20-30% at 1 year. Since 1980, survival has approached 80% 
for all comers and averages between 80-90'10 for pediatric recipients 
and 50-70% for adult recipients. The ranges cited for the survival 
figures depend primarily upon the presence or absence of prior 
195 
, 
surgeryIco~existing hepatic or biliary sepsis,and disease severity 
as determined by the performance status of the patient at the 
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time of the transplant surgery , . Specifically, those patients 
who are ICU bound prior to transplantation have the poorest pro-
gnosis with a 42% operating survival.ln contrast,are patients who 
are ill with advanced to near fatal chronic liver disease but who 
are not hospital-bound (those who are admitted solely for the 
surgical procedure rather than necessary medical care and manage-
ment of their hepatic disease prior to surgery) have a survival 
rate of 68% at I year. Those who do best, however, are those who 
are hospital-bound but not ICU-bound; they have a I-year survival 
of 84%. 
Equally important as survival, once it has been established 
that such heroic procedures can be performed with a reasonable 
chance of survival, is the quality of life which is to be expected 
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after liver transplantation ' Pediatric recipients of a liver 
transplant would appear to be the most successfully rehabilitated 
patients.Thus,87.5% of pediatric survivors are fully rehabilitated 
and free of medical problems exclusive of those associated with 
routine postoperative follow-up care aimed at the recognition 
and control of the rejection process. Normal growth and physical 
as well as psychosocial development have occurred in most. Those 
who had demonstrated either growth or psychological developmental 
delays due to their liver disease prior to transplantation usually 
demonstrate a catch-up phenomenon following transplantation. 
The quality of life data for adult liver transplant survivors 
are equally good with 85% of surviving adults returning to their 
pre-illness occupation on a full-time or regular basis following 
surgery.ln addition,several younger adult recipients have returned 
to school, others have married,and two women have had three normal 
pregnancies between them since having been transplanted. Moreover, 
when careful evaluations of psychosocial and neuropsychiatric 
parameters have been performed pre- and post-transplantation, 
consistent improvement has been noted across a wide number of 
such variables in the adults so studied. 
Now that this remarkable procedure can be shown to be accom-
plishable, and the quality of life experienced by survivors follow-
ing the procedure has been shown to be considerably better than ac-
ceptable, the next question that arises is: who are the candidates 
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for the procedure? Regardless of the nature of the primary liver 
disease mandating the procedure, several generalizations can be 
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made concerning this issue '. These are first, that acceptable 
candidates should be between I year and 50 years of age, older 
individuals are less able to survive the rigors of the procedure 
and the various cardiopulmonary challenges that accompany the 
procedure. In contrast, infants less than 1 year of age frequently 
provide a surgical challenge that is unacceptably great and as a 
resul t immmediate surgical complications are greatest in this 
group. Secondly, regardless of the age of the subject, acceptable 
candidates should be free of infection. Thus, to guarantee success, 
all pulmonary,urinary tract and hepatobiliary bacterial and fungal 
infections must be eradicated or have resolved prior to the per-
formance of the procedure. Similarly, all viral illnesses should 
be eradicated prior to transplantation. In the absence of the 
ability to eradicate such infections, as occurs with patients with 
sclerosing cholangitis, secondary biliary cirrhosis, and hepatitis 
B antigenemia, I ~ear survival rates of greater than 30-40% are 
not to be expected . 
Other conditions which mitigate against successful liver 
transplantation in patients with chronic liver disease are active 
drug or alcohol abuse, uncontrolled psychiatric disorder, primary 
extrahepatic or metastatic hepatobiliary malignancy, advanced mental 
retardation, por~al vein thrombosis, and disabling cardiopulmonary 
or renal failure .These latter two situations,however,particularly 
the last, are only relative contraindications as multiple organ 
transplants are becoming a reasonable therapeutic option and may 
in the future be applied more broadly as success with individual 
organ transplantation continues to improve. 
Acute fulminant hepatic failure has not been an important condi-
t ' h' h h ' , , 2,6,7 lon w lC as been treated to date wlth Ilver transplantatlon 
This apparently paradoxical situation obtains because such patients 
rapidly deteriorate and consideration of transplantation as a thera-
peutic option usually is initiated only after advanced coma has 
occurred. In such case, brain edema leading to herniation usually 
occurs before an appropriate donor can be identified and transplan-
tation can be accomplished. Moreover, the likelihood of recurrent 
infection in cases of fulminant viral hepatitis would seem to be 
great and therefore not warrant the procedure. 
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The conditions for which hepatic transplantation has been 
applied differ in pediatric and adult cases and are shown in 
Tables I and 2. 50% of the pediatric cases have been transplanted 
for biliary atresia. The majority of the other pediatric recipients 
have been transplanted for alpha 1 anti trypsin deficiency or 
chronic liver disease of unknown ethiology. In contrast, the 
leading conditions for which hepatic transplantation has been 
applied in adult recipients are postnecrotic cirrhosis, primary 
biliary cirrhosis and primary hepatic malignancy. 
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Table 1. INDICATIONS FOR TRANSPLANTATION IN 
PEDIATRIC PATIENTS ( 18 YEARS) 
Liver Pathology % 
Biliary atresia * 50% 
Alpha-I-antitrypsin deficiency 15% 
Chronic aggressive hepatitis 8% 
Byler's disease 8% 
Secondary biliary cirrhosis 2% 
Budd-Chiari syndrome 2% 
Neonatal hepatitis 2% 
Subacute Wilson's disease 2% 
Tyrosinemia 2% 
Type 1 glycogen storage disease 2% 
Sea-blue histiocyte syndrome 2% 
Cellular inflammatory pseudo tumor 2% 
* Two had Alagille's syndrome 
Table 2. INDICATIONS FOR TRANSPLANTATION 
IN ADULT PATIENTS ( > 19 YEARS) 
Liver Pathology % 
Postnecrotic cirrhosis 30% 
Primary biliary cirrhosis 20% 
Primary liver malignancy 18% 
Sclerosing cholangitis 12% 
Secondary biliary cirrhosis 7% 
Budd-Chiari syndrome 5% 
Alpha-I-antitrypsin deficiency 3% 
Alcoholic cirrhosis 3% 
Adenomatosis 1% 
After the three main disease conditions described above, a 
wide variety of metabolic liver diseases make up the majority of 
the other conditions for which liver transplantation has been 
8 performed in pediatric patients . In contrast, acquired liver 
diseases make up the majority of the other conditions for which 
. . 2,6,7 liver transplantation has been applled In adult cases 
Factors that make surgery more difficult and as a consequence, 
extract a toll in terms of early survival are previous surgical 
procedures, particularly those in the right upper quadrant, such 
as prior atte'o/:§s at biliary tract, reconstruction and portal 
caval shunting , . Such procedures make identification and dissec-
tion of the hilar structures more difficult and may have altered 
the anatomy further complicating the surgical dissection. More-
over, in attempts to take down a pre-existing portal caval shunt, 
the portal vein can be damaged, at times back to the confluence 
of the inferior mesenteric and splenic veins making the reesta-
blishment of portal continuity difficult, if not impossible fol-
lowing graft insertion even with the use of an iliac vein graft. 
Finally, portal hypertension, a common accompaniment of 
advanced chronic liver disease, results in the formation of 
fragile, but at times, massive venous collaterals within adhesions 
which have formed from prior surgical procedures. Such adhesions 
can lead to major problems in terms of obtaining hemostasis 
throughout the procedure from the point of host organ removal 
through attempts at obtaining hemostasis prior to closure following 
engraftment and completion of all of the vascular and biliary 
anastomoses necessitated as a result of the transplant procedure. 
Each phase is associated with its own particular difficulties 
and technical procedures have been developed for each. The most 
recent surgical advances would seem to have been made during 
phase 3, when the patient is ahepatic and consists of the creation 
of femoral and portal venous bypasses to either the internal 
jugular or more commonly the axillary veins using a heparin-free 
system which has eliminated the need for systemic heparinization. 
This technical advance has markedly reduced the rate and severity 
of postoperative bleeding while allowing that fraction of the 
cardiac output delivered to the lower body below the diaphram 
during the procedure to be returned to the heart during the per-
formance of the ahepatic phase of the operation. As a result, 
the organ engraftment can be accomplished in a careful determined 
way without the time restraints necessitated by systemic hypo-
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tension due to a declining central venous return and resultant re-
duction in cardiac output. Moreover, the immediate postoperative 
period also has been made more easy as a result of this advance. 
Specifically, as the volume of blood and colloid administered 
during the ahepatic phase of the procedure in an effort to main-
tain the cardiac output, has been reduced by this advance, the 
postengraftment volume overload experienced in terms of pulmonary 
edema has not been seen or has been reduced considerably. As a 
resul t, postoperative Intensive Care Unit time, problems with 
oxygenization and respiration usage have all been reduced. 
Postoperatively, three different phases of potential graft 
failure can be identifiable. They are: 1) early (day 1 to 5) 
technical failures due to a vascular thrombosis or biliary ana-
stomatic leak; 2) sepsis which occurs between day 3 through day 
14; and 3) rejection which is a late cause of graft failure 
usually seen during the third and fourth weeks postoperatively. 
The presenting signs of each of these three postoperative problems 
are remarkably similar and include development of a large firm 
and tender liver, increasing jaundice and fever, with or without 
an accompanying leucocytosis. Early presentation of any of these 
signs necessitates evaluation of the grafts vascular and biliary 
anastomosis. After an initial period of little or no difficulty, 
a later change in the transplant patient's condition mandates a 
search for infection in or around the liver and biliary structu-
res and finally consideration of rejection. Sonography and 
cholangiography should be attempted early when the patient's 
postoperative progress either halts or deteriorates.Early inter-
vention directed at resolving the various differential possibili-
ti7s 9 that might exist in a given case are to be pursued active-
ly , • Such procedures not only establish a specific diagnosis 
but also guide attempts at subsequent therapy such as surgical 
repair or drainage, antibiotic administ~ationI or enhanced 
immunosuppression. 
The infections that most plague patients postoperatively 
are those due to gram negative organisms and fungi that presumably 
leak into10 the surgical wound from the gut during the surgical 
procedure • Acute CMV viral infection or its reactivation appear 
to occur universally in such patients also and can be demonstrated 
by buffy coat isolation or identification of the characteristic 
changes present in urinary sediment and liver tissue obtained by 
biopsy. 
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Infection with the herpes family of viruses also occurs 
commonly postoperatively and is usuall11 manifested as either nasal 
labial genital or zoster-like lesions . Rarely, herpetic hepa-
titis occurs and can be identified by isolation of the virus from 
hepatic tissue obtained at biopsy or by using specific immuno-
histologic techniques.Candida infection of the esophagus, stomach, 
and wound are seen less often. Finally, aspergillosis and mucor 
infections also occur and may necessi tate treatment with Arrphotericin. 
As with all life extending advances in medicine ad surgery, 
new problems develop in patients so treated which are unique to 
either the procedure or the medical care necessitated by it. Thus, 
problems of chronic low grade rejection and the late development 
of recurrent hepatic failure in the transplanted organ and the 
need for a second transplant procedure should be kept in mind. To 
date, a single patient has been retransplanted late (after 5 years 
of survivorship with their original grafted organ). Similarly, 
problems occurring as a consequence of the necessary lifelong 
need for immunosuppression should be expected. These include 
those dependent upon cyclosporine administration such as nephro-
toxicity, hepatotoxicity, tremor, hypertension, seizures, gingival 
hypertrophy, increased body hair and the various other problems 
shown in Table 3. 
Table 3. RECOGNIZED CYCLOSPORINE TOXICITY 




5. gingival hypertrophy 
6. tremor 
7. cholestasis/hepatotoxicity 
8. lymphoma (?pseudolymphoma) 
9. pseudo tumor cerebri 
10. drug-drug interactions 
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The specific mechanisms responsible for the cyclosporine-
associated postoperative problems are only slowly being identi-
fied. Thus the hypertension can be shown to be due, at least 
in part, to an enhanced activation of the renin angiotension 
aldosterone system as well as an apparent angiotension independent 
12 
enhancement of systemic vascular resistance . Similarly, the 
lymphomas that have been reported to occur with cyclosporine 
use would appear to be new or reactivated Epstein Barr virus 
infections that are l~ssociated with cyclosporine use and appear 
to be dose-dependent . Thus their prevalence is greater in heart 
and renal transplantation situations which require greater 
immunosuppression than it is in liver transplant recipients. 
Moreover, on at least two occasions, the tumor has resolved when 
the cyclosporine dose has been reduced dramatically or replaced 
with Azathiaprine. It is clear that with advances in virology, 
hypertension, and tumor research which are to be expected in 
the future, these unique problems associated with cyclosporine 
use will become less and less of a problem for the transplant 
surgeon, his medical colleagues and their patients. Moreover, 
with steady refinements in surgical procedures, donor organ 
preservation and pretransplant assessment, immunotherapy and 
application of the procedure per se, success with orthotopic 
liver transplantation should improve even more. Even in the 
absence of such expected refinements it is clear that hepatic 
transplantation is here to stay, and that it has indeed, come 
of age. 
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